ArticleAnnals of medicine and surgery (2012)2026
Efficacy of Mavacamten on functional capacity in hypertrophic cardiomyopathy: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, often leading to left ventricular outflow tract (LVOT) obstruction, heart failure, and sudden cardiac death. Mavacamten, a novel cardiac myosin inhibitor, targets the underlying mechanisms of HCM. Methods: We searched PubMed, Cochrane Library, and ClinicalTrials.gov up to 1 August 2025 and included six randomized controlled trials comparing Mavacamten to placebo in adults with HCM. The primary outcome was the change in LVOT gradients (post-exercise, post-Valsalva, and resting). Secondary outcomes included N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, left ventricular ejection fraction, peak oxygen consumption (pVO Results: Among 632 patients, Mavacamten significantly reduced LVOT gradients: post-exercise (MD: -38.28 mmHg, 95% CI: -45.92 to -30.63, Conclusion: Mavacamten effectively reduces LVOT gradients and NT-proBNP levels in HCM, but its impact on exercise capacity remains uncertain, with no increased risk of SAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.